Semaglutide (Investigational)

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

The SUSTAIN 2 findings show that the glucagon-like peptide-1 analog semaglutide produces better glycemic control than the dipeptidyl peptidase-4 inhibitor sitagliptin in patients achieving inadequate control with metformin, thiazolidinediones, or both.

The SUSTAIN 4 findings show that a weekly semaglutide injection offers better metabolic and weight control than insulin in patients with diabetes that is poorly controlled on metformin.